A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511352-41-00

Acronym

1403-0002

Enrollment

Registered

2024-08-27

Start date

2022-06-13

Completion date

2025-07-16

Last updated

2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France, Germany, Hungary, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026